Debunking Human Health Risk, APPENDIX D - LBAMspray.com

LIGHT BROWN APPLE MOTH ERADICATION PROJECT
APPENDIX D
DRAFT PEIR
HUMAN HEALTH RISK ASSESSMENT
Isomate ® -LBAM Plus (Isomate) as the three proposed pheromone formulations of primary
interest for the eradication Program, as well as two microcapsule formulations CheckMate ®
LBAM-F (CheckMate) and Scentry Biologicals, Inc.’s (SBI’s) NoMate ® LBAM MEC (NoMate)
that are not currently proposed for use in the Program), (2) proposed use of Bacillus
thuringiensis kurstaki (Btk) for ground treatment, (3) proposed use of another bacterial
insecticide, spinosad, for ground treatment and (4) proposed use of permethrin with a pheromone
in male attractant treatments for ground application. In addition, evaluation of the No Program
Alternative examines the increased use of several of the chemicals currently registered for use by
the USEPA and the California Department of Pesticide Regulation (DPR) for control or
prevention of LBAM including, but not limited to, chlorpyrifos, permethrin, lambda-cyhalothrin,
spinosad, and Btk.
Table D1-1
Condensed Summary of LBAM Eradication Alternatives Evaluated in the EIR
Alternative Application Method Chemical (s)
No Program
As per label directions
Chlorpyrifos, Permethrin, Lambda-cyhalothrin, Spinosad,
Btk
Mating Disruption - 1 Twist Ties Isomate (LBAM pheromones)
Mating Disruption - 2 Ground Applications HERCON, SPLAT (LBAM pheromones)
Mating Disruption - 3 Aerial Release HERCON, SPLAT (LBAM pheromones)
Male Moth Attractant (Alternative MMA)
Ground Application
SPLAT (LBAM pheromones), Permethrin (inert
ingredients: ethylbenzene; 1,2,4-trimethylbenzene)
Organic Treatment (Alternative Bt) Ground Treatments Bacillus thuringiensis kurstaki
Organic Treatment (Alternative S, spinosad) Ground Treatments Spinosad
Inundative Parasite Wasp Release (Alternative Bio-P)
Sterile Insect Technique (Alternative SIT)
None–not considered further in this Risk Assessment
None–not considered further in this Risk Assessment
This Appendix D to the PEIR follows standard HHRA protocols (National Research Council
[NRC] 1983, 1994; California’s Office of Environmental Health Hazard Assessment [OEHHA]
2003) and addresses the four key elements of risk assessment — hazard identification,
identification of chemicals of potential concern; exposure assessment; dose-response assessment;
and risk characterization. This screening level assessment examines only potential toxicological
impacts to hypothetical human receptor populations from the use of the chemical formulations
proposed for use to eradicate LBAM. Other impact analyses are provided in the other appendices
of this report, consistent with CEQA Guidelines. Findings in this Appendix D are integrated into
the PEIR, in Section 8 Human Health and in other appropriate sections.
This screening level risk assessment uses default parameters and assumptions to assess potential
health effects of exposure to chemicals proposed for use and other chemicals previously used or
available for use under No Program. No site-specific or other data attributable to actual human
populations are used. The likelihood of adverse health effects resulting from programmatic
activities was estimated by calculating chemical-specific intakes to each of four hypothetical
receptor populations. These intakes were calculated from the estimated exposure point
concentrations (EPCs) of each of the different chemicals for each complete exposure pathway.
Estimated intakes were then compared against toxicity criteria obtained from the literature or
derived in this assessment if sufficient toxicity data were available. These comparisons were
used to evaluate whether any of the chemicals may pose potential hazards or risks to the receptor
populations.
D1-2 App D_HHRA_508.doc JULY 2009